Nathaniel Wang Email & Phone Number

Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA (srRNA) technology. srRNA's sustained protein production and orders-of-magnitude improved performance over linear mRNA will enable more treatment opportunities for more people. Differentiated by a team of srRNA experts, a customizable library of synthetic srRNA vectors, and end-to-end development capabilities, Replicate is uniquely positioned to finally expand the reach of RNA treatments toward widespread use in infectious disease, immuno-oncology, autoimmune disease, and more.

Areas of specialty: drug development, immunology, immuno-oncology, RNA medicines, platform technologies, technology scouting, landscapes, translational biology, RNA medicines CMC, vaccines, therapeutics

Raritan, New Jersey, Us

• Technology transfer and operationalization of multiple drug development programs creating new frameworks for discovery, preclinical, translational, CMC, and biomarkers in partnership with Therapeutic Area and Disease Area Stronghold heads.• Strategy and portfolio evaluation for preclinical and clinical stage assets in conjunction with cross-functional teams (R&D, business development, clinical, commercial); technology scouting and assessments.

La Jolla, Ca, Us

• Created a build-to-buy self-replicating RNA asset that yielded a >5x return on investment within 3 years; asset sold to one top 5 human health pharmaceutical company and two different top 5 animal health pharmaceutical companies.• Leads Discovery, Preclinical, and Process Development groups and reports directly to the CEO; 30+ FTEs within groups include a mixture of managers, scientists, and research associates for development of internal products or products in collaboration with external partners; managed multi-million dollar annual budgets• Executive team member leading R&D, strategy, portfolio evaluation, and program analysis for RNA and therapeutics platforms for immuno-oncology and infectious disease.• Built drug product pipeline including clinical target selection, preclinical, regulatory and manufacturing strategies, and drafting regulatory documents to support FDA INTERACT and pre-IND filings.• Created translational datasets for 10+ diseases across 5 different species in immuno-oncology and infectious disease including characterization of drug candidates for immunogenicity, efficacy, mechanism of action, biodistribution, and delivery (formulation and devices).• Leads a portfolio of matrixed programs focused on RNA platform technologies with partners including major pharma companies, biotech companies, government entities, and academic labs across infectious disease and oncology; member of multiple joint steering committees.• Led external innovation executing over 20 different asset sales, research evaluations, in-licensing, or development and commercialization agreements across vaccines and therapeutics. Led search and evaluation, tech assessments, resource identification/integration, and operationalization of partnerships to strategically advance technology.• Co-inventor on six patent applications and extensive Know How centered around the creation and delivery of distinct RNA-based platforms for vaccines, therapeutics, and bioproduction.

Raritan, New Jersey, Us

• Reported directly to the VP of Immunology and Proof-of-Concept and provided extensive scientific, developmental, and technical leadership while supervising a group of scientists and research associates both directly and within a matrix environment• Project leader responsible for preclinical proof-of-concept cancer vaccine discovery program involving creating and presenting project strategies and goals, as well as determining resourcing requirements while ensuring the execution of research according to set timelines• Built a project from an initial scientific concept to a program involving 5 different groups across 2 global sites capable of supporting at least 8 FTEs in just over 2 years• Led in vivo immunogenicity studies of vaccine candidates in murine models focused on antigen-specific T and B cell responses, epitope determination and rational design, selection and validation of immune modulators, and vaccine delivery platforms• Liaised with European and US business development, legal, and IP groups as well as CROs in anticipation of project needs relating to external collaborations, licenses, contracts, and other agreements. • Identified animal models and collaborators for in vivo efficacy studies co-authoring statements of work and driving external academic research collaborations

La Jolla, California, Us

• Discovered divergent class-specific transcriptional regulation in memory B cells. This is important for development of class-skewed vaccines and development of immunotherapeutics against memory B cells in allergies and autoimmunity• Led collaboration with a group in the Molecular Therapeutics Department to manipulate transcriptional mechanisms in IgA memory B cells using inverse agonists• Developed novel genetic models that enabled the first studies of transcriptional control of survival, re-activation, and differentiation of different classes of antigen-specific memory B cells• Created collaboration with clinicians to develop a translational science proposal for memory B cell research in vaccine development that secured independent funding• Developed and used 16-color high resolution flow cytometry analysis and cell sorting in the lab in collaboration with team members and outside companies to access rare cell populations• Investigated the dynamics of antigen-specific memory B cell and plasma cell response in vivo after immunization in diverse lymphoid organs using various immunoassays (flow cytometry, RT-PCR, single cell qPCR)

Brisbane, California, Us

• Characterized safety, specificity, efficacy, and traceability for preclinical studies of SB-728, a zinc-finger nuclease therapeutic that renders human CD4+ T cells permanently and heritably resistant to HIV infection• Explored novel methods of targeted disruption and targeted integration into endogenous loci of hematopoietic and mesenchymal stem cells allowing therapeutic modification of progenitor cells• Collaborated with a translational research group to use zinc-finger nucleases to disrupt CXCR4 in a T cell line to study simian immunodeficiency virus (SIV)• Characterized targeted editions to the human genome at predetermined sites using a zinc-finger nuclease-based nicking enzyme that creates a safer framework for targeted gene addition• Collaborated with other teams to investigate different viral-based methods of delivering zinc-finger nucleases to primary human T cells, which led to changes in the therapeutic delivery method of SB-728 used in clinical trials

South San Francisco, California, Us

• Designed and implemented a pH and conductivity validation study to improve reproducibility of manufacturing processes and increase antibody yield• Implemented validation studies for removal of viruses using tangential flow filtration (TFF) from antibody purification process

Doctor Of Philosophy (Ph.D.), Immunology

B.A., Molecular And Cellular Biology